Analytical Data
-
基因名
HLA-A*02:03&B2M&AFP(FMNKFIYEI) Tetramer
- Application
-
别名
Alpha-fetoprotein; Alpha-1-fetoprotein; Alpha-feto; AFP; HPAFP; AFPD; FETA; MHC
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
AAA03604.1 (G25-T305)&P61769
-
表达区间
AAA03604.1 (G25-T305)&P61769 (I21-M119)&FMNKFIYEI
-
分子量
260-265 kDa under Non reducing (N)
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the HLA-A*01:01 & B2M & CT83 (NTDNNLAVY) monomeric recombinant protein is significant in the field of immunology and cancer research. HLA-A*01:01 is a major histocompatibility complex (MHC) class I molecule, which plays a crucial role in presenting endogenous peptides, including tumor-specific antigens, to CD8+ cytotoxic T cells. The CT83 antigen, derived from the tumor-associated antigen CT83, is of particular interest due to its potential as a target for immunotherapy in cancers. The peptide NTDNNLAVY, presented by HLA-A*01:01, has been identified as a strong candidate for T cell recognition, making it a vital component in developing therapeutic vaccines or T cell-based treatments. Recombinant production of this protein allows for detailed characterization and analysis, enabling researchers to understand its binding affinity, stability, and immunogenicity. This knowledge aids in designing targeted therapies that can enhance the immune response against CT83-expressing tumors. Ultimately, this research contributes to the broader goal of improving cancer immunotherapy and offers potential pathways for more effective treatments against various malignancies.
